You have reached this web site because either you or your loved one suffers from a serious eye disease.
Until recently, there has not been treatment for age-related macular degeneration and the advanced eye disease eventually results in vision loss. Now the Ophthalmology Department of the Institute of Longevity and Preventive Medicine is the only place where the cure is available.
We can help you:
If your condition is dry age-related macular degeneration. If your eye disease is different please request us for additional information.
Cell therapy for macular degeneration is an advanced method when retinal stem cells are injected into periorbital area of the eye.
This is a way to overcome and reverse age-related degenerative changes in the macula and in the eye retina as a whole.
Cell therapy with retinal stem cells has revealed high efficiency of treatment for age-related eye diseases. Macular degeneration has taken for decades to develop and a combination therapy is necessary to overcome the macula degeneration.
Please note the macular degeneration is a multi-faceted condition and it is a local manifestation (i.e. degeneration of the macula) of systemic age-related body pathologies such as imbalance of cholesterol in systemic circulation, hypertension, insulin-resistance, metabolic syndrome, and other age-related diseases.
So multi-targeted combination therapy (where the therapy with retinal stem cells is the main part) is obligatory to cure the age-related macular degeneration (AMD) and exactly so treatment you will get at Ophthalmology Department of the Institute of Longevity and Preventive to cure your eye disease.
If you need our help please write in the medical survey.
What is age-related macular degeneration (AMD)?
AMD is the number one cause of legal blindness
AMD is the number one cause of legal blindness in people over the age of 50 years. Its prevalence in this age group is high and increases exponentially with increasing age. In the USA and Western Europe 15 per cent of people over 50 have some signs of AMD with one to two per cent losing significant vision as a result.
By age 85, two-thirds of people will have some AMD with 25 per cent losing vision in one or both eyes. The number of people with AMD will double in the next 20.
What is macula ?
AMD occurs with degeneration of the macula which is the part of the retina responsible for the sharp, central vision needed to read or drive. Because the macula primarily is affected in AMD, central vision loss may occur.
Early AMD and Drusen
Early AMD, also called age-related maculopathy (ARM), is characterised by the presence of two features in the macula: drusen and areas of hyper- or hypopigmentation of the retinal pigment epithelium, (RPE).
Drusen are discrete whitish-yellow extracellular deposits external to the neuro-retina and the RPE, displacing the RPE inwards. At least one intermediate sized drusen (greater than 63 microns) is considered necessary to diagnose early AMD.
While generally patients have preserved visual acuity at this stage, they may manifest other more subtle abnormalities of visual function, such as poor vision in dim light, fading vision in bright light and a central scotoma noticeable in the dark (scotoma is an area of lost or depressed vision within the visual field, surrounded by an area of less depressed or of normal vision).
Do not let your early AMD progress into advanced AMD. Start your treatment much before the loss of central vision. At the stage of early AMD the cure is much easy.